The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only claudin 18.2-targeted therapy approved in the U.S. for these indications, according to Astellas.
The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only claudin 18.2-targeted therapy approved in the U.S. for these indications, according to Astellas.